Profiles of host immune impairment in Plasmodium and SARS-CoV-2 infections

Chaturvedi, Rini; Mohan, Mradul; Kumar, Sanjeev; Chandele, Anmol; Sharma, Amit

doi:10.1016/j.heliyon.2022.e11744

Cited by 2 publications

(2 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The coronavirus-19 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) ignited intensive research on the underlying immunopathology mechanisms [reviewed in ( Rybkina et al, 2022 )]. COVID-19 and severe malaria share a hyperinflammatory response (“cytokine storm”) and several clinical manifestations, which complicates correct diagnosis and treatment of COVID-19 patients in endemic malaria regions ( Chaturvedi et al, 2022 ). Understanding the similarities in type I IFN responses between CM and COVID-19 may elucidate general mechanisms of type I IFN responses in infectious diseases.…”

Section: Type I Ifn Signaling In the Endotheliummentioning

confidence: 99%

Endothelial type I interferon response and brain diseases: identifying STING as a therapeutic target

Duarte,

Shafi,

Penha-Gonçalves

et al. 2023

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

The endothelium layer lining the inner surface of blood vessels serves relevant physiological functions in all body systems, including the exchanges between blood and extravascular space. However, endothelial cells also participate in innate and adaptive immune response that contribute to the pathophysiology of inflammatory disorders. Type I Interferon (IFN) signaling is an inflammatory response triggered by a variety of pathogens, but it can also be induced by misplaced DNA in the cytosol caused by cell stress or gene mutations. Type I IFN produced by blood leukocytes or by the endothelium itself is well-known to activate the interferon receptor (IFNAR) in endothelial cells. Here, we discuss the induction of type I IFN secretion and signaling in the endothelium, specifically in the brain microvasculature where endothelial cells participate in the tight blood-brain barrier (BBB). This barrier is targeted during neuroinflammatory disorders such as infection, multiple sclerosis, Alzheimer’s disease and traumatic brain injury. We focus on type I IFN induction through the cGAS-STING activation pathway in endothelial cells in context of autoinflammatory type I interferonopathies, inflammation and infection. By comparing the pathophysiology of two separate infectious diseases—cerebral malaria induced by Plasmodium infection and COVID-19 caused by SARS-CoV-2 infection—we emphasize the relevance of type I IFN and STING-induced vasculopathy in organ dysfunction. Investigating the role of endothelial cells as active type I IFN producers and responders in disease pathogenesis could lead to new therapeutic targets. Namely, endothelial dysfunction and brain inflammation may be avoided with strategies that target excessive STING activation in endothelial cells.

show abstract

Section: Type I Ifn Signaling In the Endotheliummentioning

confidence: 99%

Endothelial type I interferon response and brain diseases: identifying STING as a therapeutic target

Duarte,

Shafi,

Penha-Gonçalves

et al. 2023

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…COVID-19 and malaria have early symptoms that overlap, such as fever, headache, nausea, and muscular discomfort or weariness. These two diseases also have some shared concepts in the patient’s immune responses, such as cytokines and chemokines that are rapidly released during COVID-19 and Plasmodium infections, which are essential to the pathophysiology of the diseases ( Chaturvedi et al, 2022 ). The co-infection of these two diseases can pose significant challenges for healthcare systems and patients, as both diseases can cause severe illness and complications.…”

Section: Introductionmentioning

confidence: 99%

COVID-19 and malaria co-infection: a systematic review of clinical outcomes in endemic areas

Mohamed,

Eltyeb,

Said

et al. 2024

PeerJ

View full text Add to dashboard Cite

Background COVID-19 and malaria cause significant morbidity and mortality globally. Co-infection of these diseases can worsen their impact on public health. This review aims to synthesize literature on the clinical outcomes of COVID-19 and malaria co-infection to develop effective prevention and treatment strategies. Methods A comprehensive literature search was conducted using MeSH terms and keywords from the start of the COVID-19 pandemic to January 2023. The review included original articles on COVID-19 and malaria co-infection, evaluating their methodological quality and certainty of evidence. It was registered in PROSPERO (CRD42023393562). Results Out of 1,596 screened articles, 19 met the inclusion criteria. These studies involved 2,810 patients, 618 of whom had COVID-19 and malaria co-infection. Plasmodium falciparum and vivax were identified as causative organisms in six studies. Hospital admission ranged from three to 18 days. Nine studies associated co-infection with severe disease, ICU admission, assisted ventilation, and related complications. One study reported 6% ICU admission, and mortality rates of 3%, 9.4%, and 40.4% were observed in four studies. Estimated crude mortality rates were 10.71 and 5.87 per 1,000 person-days for patients with and without concurrent malaria, respectively. Common co-morbidities included Diabetes mellitus, hypertension, cardiovascular diseases, and respiratory disorders. Conclusion Most patients with COVID-19 and malaria co-infection experienced short-term hospitalization and mild to moderate disease severity. However, at presentation, co-morbidities and severe malaria were significantly associated with higher mortality or worse clinical outcomes. These findings emphasize the importance of early detection, prompt treatment, and close monitoring of patients with COVID-19 and malaria co-infection.

show abstract

Profiles of host immune impairment in Plasmodium and SARS-CoV-2 infections

Cited by 2 publications

References 94 publications

Endothelial type I interferon response and brain diseases: identifying STING as a therapeutic target

Endothelial type I interferon response and brain diseases: identifying STING as a therapeutic target

COVID-19 and malaria co-infection: a systematic review of clinical outcomes in endemic areas

Contact Info

Product

Resources

About